Lineage Cell Therapeutics (LCTX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

LCTX · Stock Price

USD 1.37+0.93 (+211.36%)

Market Cap: $337.8M

Historical price data

Market Cap: $337.8MPipeline: 3 drugsPatents: 3Founded: 1990HQ: Carlsbad, United States

Sector Ranking#49 in Cell & Gene Therapy #21 in Regenerative Medicine

Overview

Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel, allogeneic cell therapies for unmet medical needs in neurology, oncology, and ophthalmology. Its core strategy is built on the proprietary AlloSCOPE™ platform, which enables the directed differentiation of pluripotent cells into scalable, 'off-the-shelf' therapeutic products. Recent achievements include a significant collaboration with Genentech for retinal programs and advancing its lead candidate, OPC1, for spinal cord injury. The company aims to validate its platform through clinical milestones and strategic partnerships to address large, underserved markets.

NeurologyOphthalmologyOncology

Technology Platform

The AlloSCOPE™ platform is a proprietary system for the directed differentiation of pluripotent stem cells into scalable, consistent, and allogeneic ('off-the-shelf') specialized cell types for therapeutic transplantation.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
AST-OPC1	Cervical Spinal Cord Injury	Phase 1/2
OPC1	Spinal Cord Injury Cervical	Phase 1
GRNOPC1	Spinal Cord Injury	Phase 1

Funding History

2

Total raised:$26M

PIPE$16MUndisclosedDec 15, 2021

PIPE$10MUndisclosedMay 15, 2020

Opportunities

Lineage addresses massive, underserved markets like spinal cord injury and geographic atrophy where regenerative cell therapy could be transformative.

Its 'off-the-shelf' platform offers potential cost and scalability advantages over autologous therapies.

The strategic partnership with Genentech provides validation, resources, and a path to commercialization for its ocular programs.

Risk Factors

The company faces high clinical risk as all programs are in early stages with unproven efficacy.

It is pre-revenue and will require substantial additional capital, risking shareholder dilution.

Regulatory pathways for novel allogeneic cell therapies are complex and uncertain.

Competitive Landscape

Lineage competes in distinct but competitive niches: in SCI with other regenerative approaches, in dry AMD with complement inhibitors and other cell therapies, and in platform technology with other iPSC-focused companies. The Genentech partnership provides a significant competitive edge in resources and commercial potential for its retinal programs.